Axelrod et al., 2014 - Google Patents
Axl as a mediator of cellular growth and survivalAxelrod et al., 2014
View HTML- Document ID
- 5036634193552880098
- Author
- Axelrod H
- Pienta K
- Publication year
- Publication venue
- Oncotarget
External Links
Snippet
The control of cellular growth and proliferation is key to the maintenance of homeostasis. Survival, proliferation, and arrest are regulated, in part, by Growth Arrest Specific 6 (Gas6) through binding to members of the TAM receptor tyrosine kinase family. Activation of the …
- 230000004083 survival 0 title abstract description 28
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Axelrod et al. | Axl as a mediator of cellular growth and survival | |
| Gus-Brautbar et al. | The anti-inflammatory TIPE2 is an inhibitor of the oncogenic Ras | |
| Bolik et al. | Inhibition of ADAM17 impairs endothelial cell necroptosis and blocks metastasis | |
| Azarova et al. | Emerging importance of ALK in neuroblastoma | |
| Falletta et al. | Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma | |
| Nezich et al. | MiT/TFE transcription factors are activated during mitophagy downstream of Parkin and Atg5 | |
| Lennartsson et al. | Normal and oncogenic forms of the receptor tyrosine kinase kit | |
| Martinsson et al. | Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy | |
| Kyjacova et al. | IER2-induced senescence drives melanoma invasion through osteopontin | |
| US10421820B2 (en) | Bruton's tyrosine kinase as anti-cancer drug target | |
| WO2013155077A1 (en) | Response markers for src inhibitor therapies | |
| Bergamin et al. | Role of the P2X7 receptor in in vitro and in vivo glioma tumor growth | |
| Schulze et al. | RELN signaling modulates glioblastoma growth and substrate‐dependent migration | |
| Kimani et al. | Normalization of TAM post-receptor signaling reveals a cell invasive signature for Axl tyrosine kinase | |
| Basilico et al. | Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody‐“decoy” strategy | |
| Wirthschaft et al. | A PRDX1‐p38α heterodimer amplifies MET‐driven invasion of IDH‐wildtype and IDH‐mutant gliomas | |
| Nie et al. | Nuclear export signal mutation of epidermal growth factor receptor enhances malignant phenotypes of cancer cells | |
| Malikova et al. | Proteolysis of TAM receptors in autoimmune diseases and cancer: what does it say to us? | |
| MX2014011686A (en) | C-raf mutants that confer resistance to raf inhibitors. | |
| Nishi et al. | An alpha-kinase 2 gene variant disrupts filamentous actin localization in the surface cells of colorectal cancer spheroids | |
| Sayedyahossein et al. | Pannexin 1 crosstalk with the Hippo pathway in malignant melanoma | |
| Hinz et al. | Modeling acquired TKI resistance and effective combination therapeutic strategies in murine RET+ lung adenocarcinoma | |
| Axelrod | The role of AXL in prostate cancer dormancy | |
| García-Colomer et al. | Rapamycin can revert CCM phenotype in brain endothelial cells and ameliorates chronic cavernoma development in combination with lapatinib | |
| Quach | The effects of Lin28a and its phosphorylation at S200 on Imatinib resistance in chronic myeloid leukemia |